LEADER 03921nam  2200589 a 450 
001 9910778061003321
005 20231010180100.0
010   $a90-6299-849-6
035   $a(CKB)1000000000773964
035   $a(EBL)449440
035   $a(OCoLC)609842303
035   $a(SSID)ssj0000360573
035   $a(PQKBManifestationID)12111113
035   $a(PQKBTitleCode)TC0000360573
035   $a(PQKBWorkID)10344288
035   $a(PQKB)11586480
035   $a(MiAaPQ)EBC449440
035   $a(Au-PeEL)EBL449440
035   $a(CaPaEBR)ebr10505624
035   $a(EXLCZ)991000000000773964
100   $a20111129d2008      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGlaucoma screening $escreening for open angle glaucoma, primary angle-closure and primary angle-closure glaucoma : the 5th consensus report of the World Glaucoma Association /$fedited by Robert N. Weinreb, Paul R. Healey and Fotis Topouzis
210   $aAmsterdam $cKugler Publications$d[2008]
215   $a1 online resource (165 pages)
225 1 $aConsensus series
311 0 $a90-6299-218-8 
320   $aIncludes bibliographical references and index.
327   $aFACULTY; CONTENTS; PREFACE; WELCOME; SCREENING FOR OPEN-ANGLE GLAUCOMA (OAG); IS OAG AN IMPORTANT HEALTH; IS THERE AN ACCEPTED AND EFFECTIVE TREATMENT FOR PATIENTS WITH THE DISEASE THAT IS MORE EFFECTIVE AT PREVENTING MORBIDITY WHEN INITIATED IN THE EARLY, ASYMPTOMATIC STAGE THAN WHEN BEGUN IN THE LATER,; ARE FACILITIES FOR DIAGNOSIS AND TREATMENT AVAILABLE?; IS THERE AN APPROPRIATE, ACCEPTABLE, AND REASONABLY ACCURATE SCREENING TEST?; IS THE NATURAL HISTORY OF THE CONDITION, INCLUDING DEVELOPMENT FROM LATENT TO MANIFEST DISEASE, ADEQUATELY UNDERSTOOD?
327   $aIS THE COST OF CASE FINDING (INCLUDING DIAGNOSIS AND TREATMENT OF PATIENTS DIAGNOSED) ECONOMICALLY BALANCED IN RELATION TO POSSIBLE EXPENDITURE ON MEDICAL CARE AS A WHOLE?SCREENING FOR PRIMARY ANGLE CLOSURE AND PRIMARY ANGLE-CLOSURE GLAUCOMA; ARE ANGLE CLOSURE (AC) AND ANGLE-CLOSURE GLAUCOMA (ACG) IMPORTANT HEALTH PROBLEMS?; IS THERE AN ACCEPTED AND EFFECTIVE TREATMENT FOR PATIENTS WITH ANGLE-CLOSURE GLAUCOMA (ACG) THAT IS MORE EFFECTIVE AT PREVENTING MORBIDITY WHEN INITIATED IN THE EARLY, ASYMPTOMATIC STAGE THAN WHEN BEG; ARE FACILITIES FOR DIAGNOSIS AND TREATMENT AVAILABLE?
327   $aIS THERE AN APPROPRIATE, ACCEPTABLE, AND REASONABLY ACCURATE SCREENING TEST?; IS THE NATURAL HISTORY OF THE CONDITION, INCLUDING DEVELOPMENT FROM LATENT TO MANIFEST DISEASE, ADEQUATELY UNDERSTOOD?; IS THE COST OF CASE FINDING (INCLUDING DIAGNOSIS AND TREATMENT OF PATIENTS DIAGNOSED) ECONOMICALLY BALANCED IN RELATION TO POSSIBLE EXPENDITURE ON MEDICAL CARE AS A WHOLE?; INDEX OF AUTHORS; SUMMARY CONSENSUS POINTS
330   $aThis is the fifth glaucoma World Glaucoma Association Consensus. As with other consensus topics, the discussion and conclusions of Glaucoma Screening, the subject for the 2008 consensus, will have broad impact. The global faculty, consisting of leading authorities on various aspects of glaucoma screening, met in Fort Lauderdale on April 26, 2008 to discuss the reports and refine the consensus statements. The Consensus Panel also met at that time, as well as electronically during the subsequent four weeks.
410  0$aConsensus series (World Glaucoma Association) ;$v5.
606   $aGlaucoma$xDiagnosis
615  0$aGlaucoma$xDiagnosis.
676   $a617.7/41
676   $a617.741
701   $aWeinreb$b Robert N.$f1949-$01475354
701   $aHealey$b Paul R$0962613
701   $aTopouzis$b Fotis$01522773
712 02$aWorld Glaucoma Association.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910778061003321
996   $aGlaucoma screening$93762651
997   $aUNINA